Loading…
NovaBay Pharmaceuticals, Inc. received an FDA Warning Letter on November 2, 2020, regarding drug products. Based on the limited metadata available, the specific violations and their nature cannot be determined, as the subject line and detailed violation information are not provided. The letter was issued by the FDA's drug regulatory division, though the specific issuing office is unknown. To understand the full scope of regulatory concerns, the complete Warning Letter text would be needed.